INTRODUCTION: persistent severe asthma represent a high cost to health system. Among patients with asthma, represent more than 50% of health’s care spend. This outcome is mainly due to high frequency at use of hospitalizations and urgencies. In one year, the patient’s proportion that use those services could be more than 52%. OBJECTIVES:: determine the impact generated by a drug-safety program on the hospitalization of the target population. METHODS:: paired samples study (1 year before and after). Recruitment period was between May 2013 and June 2015 in Antioquia, Valle, Atlantico and Cundinamarca. Population was diagnosed with persistent severe asthma; they started pharmacological treatment with Omalizumab and education every month by a pharmacist from a drug-safety program (post-test). Education was focus on medication correct use and pharmacological adherence importance. Dependent variables were hospitalization proportion and hospitalization rate. Absolute and relative frequencies were used, summary measure (central tendency, scatter and position). Normality test were performed (Kolmogorov-Smirnov) and association test (t-Wilcoxon y McNemar). Confidence interval 95% and standard error 5% were used. RESULTS:: the evaluated population (n: 237) predominated for being adherent (85%), use correctly medication (90%), women gender (70%), adults (36 [IR 19-54] years), workers (37%) or students (27%), with low schooling level (77% ≤ high school) and low socio-economic level (85% ≤ 3), from urban area (95%) from Antioquia department (91%). 14.8% presented at least 1 hospitalization before and 8% after (P-value: 0.008). Hospitalizations number per each 100 patients was 21 before and 12 after (P-value: 0.012). CONCLUSIONS:: ensuring the correct usage and sufficient adherence of Omalizumab contributed to decrease of hospitalization frequency and rate.